Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients.

Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, Mercer R, van Bokhoven A, Torkko KC, Agarwal C, Agarwal R, Abd Elmageed ZY, Yadav H, Mishra SK, Deep G.

Cancer Med. 2019 Mar;8(3):1110-1123. doi: 10.1002/cam4.1885. Epub 2019 Jan 8.

2.

Phase II Trial of Acai Juice Product in Biochemically Recurrent Prostate Cancer.

Kessler ER, Su LJ, Gao D, Torkko KC, Wacker M, Anduha M, Chronister N, Maroni P, Crawford ED, Flaig TW, Glode LM, Lam ET.

Integr Cancer Ther. 2018 Dec;17(4):1103-1108. doi: 10.1177/1534735418803755. Epub 2018 Oct 5.

3.

A Role for Tryptophan-2,3-dioxygenase in CD8 T-cell Suppression and Evidence of Tryptophan Catabolism in Breast Cancer Patient Plasma.

Greene LI, Bruno TC, Christenson JL, D'Alessandro A, Culp-Hill R, Torkko K, Borges VF, Slansky JE, Richer JK.

Mol Cancer Res. 2019 Jan;17(1):131-139. doi: 10.1158/1541-7786.MCR-18-0362. Epub 2018 Aug 24.

PMID:
30143553
4.

Interobserver Variation among Pathologists and Refinement of Criteria in Distinguishing Separate Primary Tumors from Intrapulmonary Metastases in Lung.

Nicholson AG, Torkko K, Viola P, Duhig E, Geisinger K, Borczuk AC, Hiroshima K, Tsao MS, Warth A, Lantuejoul S, Russell PA, Thunnissen E, Marchevsky A, Mino-Kenudson M, Beasley MB, Botling J, Dacic S, Yatabe Y, Noguchi M, Travis WD, Kerr K, Hirsch FR, Chirieac LR, Wistuba II, Moreira A, Chung JH, Chou TY, Bubendorf L, Chen G, Pelosi G, Poleri C, Detterbeck FC, Franklin WA.

J Thorac Oncol. 2018 Feb;13(2):205-217. doi: 10.1016/j.jtho.2017.10.019. Epub 2017 Nov 7.

5.

Fascin Is Associated With Aggressive Behavior and Poor Outcome in Uterine Carcinosarcoma.

Richmond AM, Blake EA, Torkko K, Smith EE, Spillman MA, Post MD.

Int J Gynecol Cancer. 2017 Nov;27(9):1895-1903. doi: 10.1097/IGC.0000000000001077.

PMID:
28704324
6.

Synergy between Androgen Receptor Antagonism and Inhibition of mTOR and HER2 in Breast Cancer.

Gordon MA, D'Amato NC, Gu H, Babbs B, Wulfkuhle J, Petricoin EF, Gallagher I, Dong T, Torkko K, Liu B, Elias A, Richer JK.

Mol Cancer Ther. 2017 Jul;16(7):1389-1400. doi: 10.1158/1535-7163.MCT-17-0111. Epub 2017 May 3.

7.

Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial.

Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML.

Nutrients. 2017 Apr 12;9(4). pii: E378. doi: 10.3390/nu9040378.

8.

Cooperative Dynamics of AR and ER Activity in Breast Cancer.

D'Amato NC, Gordon MA, Babbs B, Spoelstra NS, Carson Butterfield KT, Torkko KC, Phan VT, Barton VN, Rogers TJ, Sartorius CA, Elias A, Gertz J, Jacobsen BM, Richer JK.

Mol Cancer Res. 2016 Nov;14(11):1054-1067. Epub 2016 Aug 26.

9.

Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancers.

Gari HH, Gearheart CM, Fosmire S, DeGala GD, Fan Z, Torkko KC, Edgerton SM, Lucia MS, Ray R, Thor AD, Porter CC, Lambert JR.

Oncotarget. 2016 Mar 29;7(13):15757-71. doi: 10.18632/oncotarget.7462.

10.

Prostate Biopsy Markers of Inflammation are Associated with Risk of Clinical Progression of Benign Prostatic Hyperplasia: Findings from the MTOPS Study.

Torkko KC, Wilson RS, Smith EE, Kusek JW, van Bokhoven A, Lucia MS.

J Urol. 2015 Aug;194(2):454-61. doi: 10.1016/j.juro.2015.03.103. Epub 2015 Mar 28.

PMID:
25828974
11.

Active Surveillance is an Appropriate Management Strategy for a Proportion of Men Diagnosed with Prostate Cancer by Prostate Specific Antigen Testing.

Overholser S, Nielsen M, Torkko K, Cwilka D, Weaver B, Shi X, Leach RJ, Hernandez J, Huang T, Thompson IM Jr, Thompson IM 3rd.

J Urol. 2015 Sep;194(3):680-4. doi: 10.1016/j.juro.2015.01.089. Epub 2015 Jan 28.

PMID:
25636657
12.

Reduced expression of GDF-15 is associated with atrophic inflammatory lesions of the prostate.

Lambert JR, Whitson RJ, Iczkowski KA, La Rosa FG, Smith ML, Wilson RS, Smith EE, Torkko KC, Gari HH, Lucia MS.

Prostate. 2015 Feb 15;75(3):255-65. doi: 10.1002/pros.22911. Epub 2014 Oct 18.

13.

Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial.

Schenk JM, Till CA, Tangen CM, Goodman PJ, Song X, Torkko KC, Kristal AR, Peters U, Neuhouser ML.

Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1484-93. doi: 10.1158/1055-9965.EPI-13-1340.

14.

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide.

Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D'Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J, Gómez F, Medicherla S, Alfaro IE, McCullagh E, Jedlicka P, Torkko KC, Thor AD, Elias AD, Protter AA, Richer JK.

Breast Cancer Res. 2014 Jan 22;16(1):R7. doi: 10.1186/bcr3599.

15.

Prostatic atrophy: its spatial proximity to carcinoma and intraepithelial neoplasia based on annotation of digital slides.

Iczkowski KA, Torkko KC, Wilson RS, Lucia MS, Bostwick DG.

Hum Pathol. 2014 Jan;45(1):54-8. doi: 10.1016/j.humpath.2013.07.041. Epub 2013 Oct 21.

PMID:
24157066
16.

Anterior tumors of the prostate: diagnosis and significance.

Werahera PN, Crawford ED, La Rosa FG, Torkko KC, Schulte B, Sullivan HT, van Bokhoven A, Lucia MS, Kim FJ.

Can J Urol. 2013 Oct;20(5):6897-906.

17.

Tolerance of the human kidney to isolated controlled ischemia.

Parekh DJ, Weinberg JM, Ercole B, Torkko KC, Hilton W, Bennett M, Devarajan P, Venkatachalam MA.

J Am Soc Nephrol. 2013 Feb;24(3):506-17. doi: 10.1681/ASN.2012080786. Epub 2013 Feb 14.

18.

Pseudolumen size and perimeter in prostate cancer: correlation with patient outcome.

Iczkowski KA, Torkko KC, Kotnis GR, Wilson RS, Huang W, Wheeler TM, Abeyta AM, Lucia MS.

Prostate Cancer. 2011;2011:693853. doi: 10.1155/2011/693853. Epub 2011 Jul 14.

19.

Digital quantification of five high-grade prostate cancer patterns, including the cribriform pattern, and their association with adverse outcome.

Iczkowski KA, Torkko KC, Kotnis GR, Wilson RS, Huang W, Wheeler TM, Abeyta AM, La Rosa FG, Cook S, Werahera PN, Lucia MS.

Am J Clin Pathol. 2011 Jul;136(1):98-107. doi: 10.1309/AJCPZ7WBU9YXSJPE.

20.

Differential expression of transferrin receptor (TfR) in a spectrum of normal to malignant breast tissues: implications for in situ and invasive carcinoma.

Singh M, Mugler K, Hailoo DW, Burke S, Nemesure B, Torkko K, Shroyer KR.

Appl Immunohistochem Mol Morphol. 2011 Oct;19(5):417-23. doi: 10.1097/PAI.0b013e318209716e.

PMID:
21297444
21.

p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia.

Samarawardana P, Dehn DL, Singh M, Franquemont D, Thompson C, Gaido L, Torkko KC, Homer P, Burke S, Titmus MA, Nayi V, Shroyer KR.

Cancer Cytopathol. 2010 Jun 25;118(3):146-56. doi: 10.1002/cncy.20078. Erratum in: Cancer Cytopathol. 2010 Oct 25;118(5):303.

22.

B7-H4 expression in Brenner tumours, a descriptive and comparative study.

Yee EU, Zaino RJ, Torkko KC, Shroyer KR.

Histopathology. 2010 Apr;56(5):652-4. doi: 10.1111/j.1365-2559.2010.03516.x. No abstract available.

PMID:
20459576
23.

The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE.

Cancer Res. 2008 Aug 1;68(15):6387-95. doi: 10.1158/0008-5472.CAN-08-0538.

24.

ZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease.

Singh M, Spoelstra NS, Jean A, Howe E, Torkko KC, Clark HR, Darling DS, Shroyer KR, Horwitz KB, Broaddus RR, Richer JK.

Mod Pathol. 2008 Jul;21(7):912-23. doi: 10.1038/modpathol.2008.82. Epub 2008 May 16.

25.

VDR and SRD5A2 polymorphisms combine to increase risk for prostate cancer in both non-Hispanic White and Hispanic White men.

Torkko KC, van Bokhoven A, Mai P, Beuten J, Balic I, Byers TE, Hokanson JE, Norris JM, Barón AE, Lucia MS, Thompson IM, Leach RJ.

Clin Cancer Res. 2008 May 15;14(10):3223-9. doi: 10.1158/1078-0432.CCR-07-4894.

26.

Detection of B7-H4 and p53 in pancreatic cancer: potential role as a cytological diagnostic adjunct.

Awadallah NS, Shroyer KR, Langer DA, Torkko KC, Chen YK, Bentz JS, Papkoff J, Liu W, Nash SR, Shah RJ.

Pancreas. 2008 Mar;36(2):200-6. doi: 10.1097/MPA.0b013e318150e4e0.

PMID:
18376314
27.

Preoperative prediction of unifocal, unilateral, margin-negative, and small volume prostate cancer.

Iczkowski KA, Hossain D, Torkko KC, Qian J, Lucia MS, Wheeler TM, Rewcastle JC, Bostwick DG.

Urology. 2008 Jun;71(6):1166-71. doi: 10.1016/j.urology.2007.10.013. Epub 2008 Feb 15.

PMID:
18279927
28.

B7-h4 expression in a range of breast pathology: correlation with tumor T-cell infiltration.

Mugler KC, Singh M, Tringler B, Torkko KC, Liu W, Papkoff J, Shroyer KR.

Appl Immunohistochem Mol Morphol. 2007 Dec;15(4):363-70.

PMID:
18091377
29.

Trials of new germ cell immunohistochemical stains in 93 extragonadal and metastatic germ cell tumors.

Iczkowski KA, Butler SL, Shanks JH, Hossain D, Schall A, Meiers I, Zhou M, Torkko KC, Kim SJ, MacLennan GT.

Hum Pathol. 2008 Feb;39(2):275-81. Epub 2007 Nov 28. Erratum in: Hum Pathol. 2013 Dec;44(12):2873.

PMID:
18045648
30.

Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans.

Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, Leach RJ.

Clin Cancer Res. 2007 Oct 1;13(19):5959-64.

31.

Effect of tamoxifen on endometrial histology, hormone receptors, and cervical cytology: a prospective study with follow-up.

Leslie KK, Walter SA, Torkko K, Stephens JK, Thompson C, Singh M.

Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):284-93.

PMID:
17721273
32.

B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration.

Miyatake T, Tringler B, Liu W, Liu SH, Papkoff J, Enomoto T, Torkko KC, Dehn DL, Swisher A, Shroyer KR.

Gynecol Oncol. 2007 Jul;106(1):119-27. Epub 2007 May 16.

PMID:
17509674
33.

Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma.

Dehn D, Torkko KC, Shroyer KR.

Cancer. 2007 Feb 25;111(1):1-14. Review.

34.

Steroid receptor coactivator AIB1 in endometrial carcinoma, hyperplasia and normal endometrium: Correlation with clinicopathologic parameters and biomarkers.

Balmer NN, Richer JK, Spoelstra NS, Torkko KC, Lyle PL, Singh M.

Mod Pathol. 2006 Dec;19(12):1593-605. Epub 2006 Sep 15.

35.

Association between an estrogen receptor alpha gene polymorphism and the risk of prostate cancer in black men.

Hernández J, Balic I, Johnson-Pais TL, Higgins BA, Torkko KC, Thompson IM, Leach RJ.

J Urol. 2006 Feb;175(2):523-7.

PMID:
16406987
36.

B7-H4 overexpression in ovarian tumors.

Tringler B, Liu W, Corral L, Torkko KC, Enomoto T, Davidson S, Lucia MS, Heinz DE, Papkoff J, Shroyer KR.

Gynecol Oncol. 2006 Jan;100(1):44-52. Epub 2005 Oct 26.

PMID:
16256178
37.

Clinical staging of prostate cancer: a computer-simulated study of transperineal prostate biopsy.

Crawford ED, Wilson SS, Torkko KC, Hirano D, Stewart JS, Brammell C, Wilson RS, Kawata N, Sullivan H, Lucia MS, Werahera PN.

BJU Int. 2005 Nov;96(7):999-1004.

38.

B7-h4 is highly expressed in ductal and lobular breast cancer.

Tringler B, Zhuo S, Pilkington G, Torkko KC, Singh M, Lucia MS, Heinz DE, Papkoff J, Shroyer KR.

Clin Cancer Res. 2005 Mar 1;11(5):1842-8.

39.

Biomorphometric analysis of human prostatic carcinoma by using three-dimensional computer models.

Werahera PN, Miller GJ, Torkko K, Crawford ED, Stewart JS, Deantoni EP, Miller HL, Lucia MS.

Hum Pathol. 2004 Jul;35(7):798-807.

PMID:
15257542
40.

Inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale.

Lucia MS, Torkko KC.

J Urol. 2004 Feb;171(2 Pt 2):S30-4; discussion S35. Review.

PMID:
14713750
41.

Laterally directed biopsies detect more clinically threatening prostate cancer: computer simulated results.

Kawata N, Miller GJ, Crawford ED, Torkko KC, Stewart JS, Lucia MS, Miller HL, Hirano D, Werahera PN.

Prostate. 2003 Oct 1;57(2):118-28.

PMID:
12949935
42.

Natural history of prostate cancer--epidemiologic considerations.

Miller GJ, Torkko KC.

Epidemiol Rev. 2001;23(1):14-8. Review.

PMID:
11588839
43.
44.
45.

Enlarged motor units resulting from partial denervation of cat hindlimb muscles.

Luff AR, Hatcher DD, Torkko K.

J Neurophysiol. 1988 May;59(5):1377-94.

PMID:
3385465

Supplemental Content

Loading ...
Support Center